相似文献
1
Structure and function of respiratory syncytial virus surface glycoproteins.
Curr Top Microbiol Immunol. 2013;372:83-104. doi: 10.1007/978-3-642-38919-1_4.
2
Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
Vaccine. 2019 Sep 24;37(41):6112-6124. doi: 10.1016/j.vaccine.2019.07.089. Epub 2019 Aug 12.
3
Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.
Eur J Clin Microbiol Infect Dis. 2018 Oct;37(10):1817-1827. doi: 10.1007/s10096-018-3289-4. Epub 2018 Jun 6.
4
Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
J Virol. 2019 Nov 13;93(23). doi: 10.1128/JVI.00914-19. Print 2019 Dec 1.
5
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Vaccine. 2018 Dec 18;36(52):8069-8078. doi: 10.1016/j.vaccine.2018.10.073. Epub 2018 Oct 30.
6
Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins.
Antiviral Res. 2014 Nov;111:129-35. doi: 10.1016/j.antiviral.2014.09.005. Epub 2014 Sep 18.
7
Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
Clin Vaccine Immunol. 2016 Jun 6;23(6):451-9. doi: 10.1128/CVI.00720-15. Print 2016 Jun.
8
Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.
J Virol. 2014 Apr;88(8):4237-50. doi: 10.1128/JVI.03481-13. Epub 2014 Jan 29.
9
Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
J Virol. 2015 Sep;89(18):9499-510. doi: 10.1128/JVI.01373-15. Epub 2015 Jul 8.
10
Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies.
PLoS Pathog. 2018 Mar 6;14(3):e1006935. doi: 10.1371/journal.ppat.1006935. eCollection 2018 Mar.
引用本文的文献
1
Quantification of RSV Antibodies in Human Plasma by Enzyme Immunoassays.
Methods Mol Biol. 2025;2948:365-374. doi: 10.1007/978-1-0716-4666-3_23.
2
Expression and Purification of Recombinant Respiratory Syncytial Virus Proteins.
Methods Mol Biol. 2025;2948:137-157. doi: 10.1007/978-1-0716-4666-3_10.
3
Secretory Expression and Purification of Respiratory Syncytial Virus G and F Ectodomain in Human Cells.
Methods Mol Biol. 2025;2948:127-135. doi: 10.1007/978-1-0716-4666-3_9.
4
Respiratory Syncytial Virus Fusion Activity Syncytia Assay.
Methods Mol Biol. 2025;2948:73-83. doi: 10.1007/978-1-0716-4666-3_5.
5
Introduction to Respiratory Syncytial Virus.
Methods Mol Biol. 2025;2948:1-17. doi: 10.1007/978-1-0716-4666-3_1.
6
Genomic characterization and phylogenetic analysis of respiratory syncytial virus F gene in Sri Lanka: a comparative study.
BMC Genom Data. 2025 Jul 29;26(1):52. doi: 10.1186/s12863-025-01343-0.
7
Molecular characterization of human respiratory syncytial virus in Mexico (season 2023-2024) through whole-genome sequencing.
Sci Rep. 2025 Jul 28;15(1):27382. doi: 10.1038/s41598-025-13061-9.
8
Hospitalizations for respiratory syncytial virus (RSV) in Sicily from 2008 to 2021: clinical features and predictors of severity.
Ital J Pediatr. 2025 Jul 2;51(1):205. doi: 10.1186/s13052-025-01998-6.
9
Genomic Epidemiology of Respiratory Syncytial Virus in a New England Hospital System, 2024.
Open Forum Infect Dis. 2025 Jun 18;12(6):ofaf334. doi: 10.1093/ofid/ofaf334. eCollection 2025 Jun.
10
Development and Validation of a New Set of Primers for Identification of Circulating Lineages and Palivizumab/Nirsevimab Resistance in HRSV Isolates from Cabo Verde.
Trop Med Infect Dis. 2025 Jun 10;10(6):160. doi: 10.3390/tropicalmed10060160.
本文引用的文献
1
Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody.
Science. 2013 May 31;340(6136):1113-7. doi: 10.1126/science.1234914. Epub 2013 Apr 25.
2
The secreted G protein of human respiratory syncytial virus antagonizes antibody-mediated restriction of replication involving macrophages and complement.
J Virol. 2012 Oct;86(19):10880-4. doi: 10.1128/JVI.01162-12. Epub 2012 Jul 25.
3
Viroporins: structure and biological functions.
Nat Rev Microbiol. 2012 Jul 2;10(8):563-74. doi: 10.1038/nrmicro2820.
4
The small hydrophobic protein of the human respiratory syncytial virus forms pentameric ion channels.
J Biol Chem. 2012 Jul 13;287(29):24671-89. doi: 10.1074/jbc.M111.332791. Epub 2012 May 23.
5
Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains.
Viral Immunol. 2012 Jun;25(3):193-203. doi: 10.1089/vim.2011.0094. Epub 2012 May 2.
6
The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodents.
PLoS One. 2012;7(3):e34331. doi: 10.1371/journal.pone.0034331. Epub 2012 Mar 29.
7
Genetic variability of human respiratory syncytial virus A strains circulating in Ontario: a novel genotype with a 72 nucleotide G gene duplication.
PLoS One. 2012;7(3):e32807. doi: 10.1371/journal.pone.0032807. Epub 2012 Mar 28.
8
In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo.
Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5040-5. doi: 10.1073/pnas.1110203109. Epub 2012 Mar 12.
9
Dual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvant.
PLoS One. 2012;7(2):e32226. doi: 10.1371/journal.pone.0032226. Epub 2012 Feb 27.
10
Targeting RSV with vaccines and small molecule drugs.
Infect Disord Drug Targets. 2012 Apr;12(2):110-28. doi: 10.2174/187152612800100143.
Zotero 插件